Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Spectrum Healthcare Partners Taps Proscia to Democratize Cancer Diagnosis

Proscia
By Author Proscia | March 13, 2023

Proscia announced that Spectrum Healthcare Partners, an independent, multispecialty, physician-owned healthcare practice, has selected Concentriq Dx* to modernize its pathology operations.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

Our website uses cookies. By using this site, you agree to its use of cookies.